Efficacy And Safety Evaluation Rencently Of Low-Dose Ticagrelor In Patients With Non-ST Elevation Acute Coronary Syndrome After PCI

Objectives: Objective to evaluate the efficacy and safety of low-dose ticagrelor in patients with non-ST elevation acute coronary syndrome after PCI.Methods:1.Sixty patients with NSTACS in our department of cardiology were enrolled.After successful enrollment,they were randomly divided into 2 groups,30 in each group.Basic information was asked.At the same time,three months of follow-up were performed to record the platelet MAR,AAR,and INH in the first month,the second month,and the third month.Record bleeding events and adverse reactions.2.The counting data is described by the number of cases(percentage),and the chi-square test is used to compare between groups.The normality test is performed on the measurement data.Since the measurement data involved in this paper do not obey the normal distribution,it is used.The number of digits(lower quartile to upper quartile)is described by way of rank sum test for comparison between groups.Repeated measures of variance analysis were used to compare changes in platelet index at different time points after administration.The test level α of the above test is 0.05,and the statistical software is SPSS 25.0.Results:1.Two groups of patients received ticagrelor 1 month to test the platelet function of MAR,the standard dose group and the low dose group after the first month,the result was 26.80%(21.08-37.83)vs.23.35%(13.98-48.33).After the second month,the results were 22.35%(19.48-30.30)vs 26.00%(17.05-44.53).After the third month,the results were 19.60%(13.53-25.23)vs 31.40%(18.68-42.00).2.Two groups of patients received ticagrelor 1 month to test the plateletfunction of AAR,the standard dose group and the low dose group after the first month,the result was 23.45%(13.25-36.63)vs21.50%(12.43-39.73).After the second month,the results were 19.50%(12.48-27.73)vs 23.30%(12.65-40.30).After the third month,the results were 15.30%(7.40-23.48)vs 27.40%(16.63-38.00).3.Two groups of patients received ticagrelor 1 month to test the platelet function of INH,the standard dose group and the low dose group after the first month,the results were 73.70%(60.68-79.33)vs75.25%(51.68-85.20).After the second month,the results were 79.60%(69.48-81.75)vs 74.20%(55.40~84.50).After the third month,the results were 82.30%(74.38-85.78)vs 72.35%(61.15~81.30).4.There was no significant difference in the incidence of MACCE and the incidence of secondary bleeding between the two groups(P>0.05),including 1 case of ecchymoses(3.30%)and 2 cases of thrombocytopenia in the standard dose of ticagrelor.(6.60%)patients.There were 3 patients with ecchymosis(10.00%)in the low-dose ticagrelor group.Conclutions:1.The low-dose ticagrelor and the standard dose of ticagrelor have similar antiplatelet effects,and no MACEE events have occurred in the near future.2.Low-dose ticagrelor has the same risk of fatal bleeding as the standard dose of ticagrelor,with no fatal bleeding events,suggesting that secondary bleeding events with low-dose ticagrelor are less risky than standard doses of ticagrelor..